|
**Overview**: Coagulation Screen Panel**Introduction**: The Coagulation Screen Panel is a diagnostic tool designed to screen for coagulation disorders using plasma samples. In India, bleeding disorders (hemophilia, von Willebrand disease, vitamin K deficiency, liver disease) and thrombotic risks (DVT, PE) are significant, with hemophilia prevalence ~1 in 10,000 males and acquired coagulopathies common in liver disease/malnutrition. High morbidity from underdiagnosis in rural/low-SES populations, limited hematology labs, delayed factor replacement or anticoagulation leading to hemorrhage or thrombosis. Per hematology practices aligned with ICMR and Indian Society of Hematology guidelines, the test employs coagulation analyzer for PT, aPTT, INR, fibrinogen, D-dimer, thrombin time, platelet count over 1-2 days with high accuracy, valuable for initial bleeding/thrombosis evaluation. This diagnostic falls under bleeding disorder screening and targets patients with unexplained bleeding, bruising, or thrombosis risk, addressing accurate detection to guide factor concentrates, vitamin K, or anticoagulants. With elevated morbidity due to underdiagnosis, the test supports public health efforts by enabling precise identification and reducing complications. Its plasma-based approach ensures reliable performance.**Other Names**: Coag Scr Pnl.**FDA Status**: FDA approved, CLIA certified for hematology, compliant with 2025 standards.**Historical Milestone**: Standard coagulation panel; in India, essential in hemophilia care centers.**Purpose**: The test screens for 7 parameters including PT and aPTT to guide coagulation disorder assessment, detect bleeding/thrombotic risks, inform therapy.**Test Parameters**: 1. PT, 2. aPTT, 3. INR, 4. Fibrinogen, 5. D-Dimer, 6. Platelet Count, 7. Thrombin Time.**Pretest Condition**: No fasting required; patients should report bleeding, bruising, thrombosis, or family history.**Specimen**: 3 mL plasma in 1 NaCit tube, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 8 hours with proper handling to preserve analyte integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: 6 months at -20 degrees Celsius, allowing long-term storage for retesting, though freezing may affect some analytes.**Medical History**: Patients should provide details on bleeding episodes, thrombosis, liver disease, medications, family bleeding history.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of untreated coagulation disorders including hemorrhage or thrombosis, benefits of early detection, and minimal discomfort from blood draw.**Procedural Considerations**: The test involves sample processing using coagulation analyzer by trained personnel to ensure sterile technique, avoid hemolysis, and interpret results within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols, and store kits according to manufacturer specifications to ensure reliability.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, hemolysis, or anticoagulants can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Abnormal results indicate coagulation disorder, necessitating specialist input. Normal may require follow-up if symptoms persist.**Specialist Consultation**: Hematologists should be consulted for management.**Additional Supporting Tests**: Factor assays, mixing studies for confirmation.**Test Limitations**: May miss mild deficiencies; comprehensive approach required.**References**: Indian Journal of Hematology 2024, Coagulation Studies India 2023. |
